1 – 67 of 67
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
PSA : role in screening and monitoring patients with prostate cancer
2022) p.131-172(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2021
-
Mark
Identification of a serum biomarker signature associated with metastatic prostate cancer
(
- Contribution to journal › Article
-
Mark
Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing
(
- Contribution to journal › Article
-
Mark
High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
2020) In Proceedings of the National Academy of Sciences of the United States of America 117(26). p.15172-15181(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels
(
- Contribution to journal › Article
- 2019
-
Mark
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
(
- Contribution to journal › Article
-
Mark
The role of plasma microseminoprotein-beta in prostate cancer : An observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition
(
- Contribution to journal › Article
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
-
Mark
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men
2019) In Prostate(
- Contribution to journal › Article
-
Mark
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy : An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
(
- Contribution to journal › Article
- 2018
-
Mark
Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival
(
- Contribution to journal › Article
-
Mark
Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL : results from the Göteborg randomized population-based prostate cancer screening trial
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age : Data from the malmö preventive project
(
- Contribution to journal › Article
-
Mark
Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial : effect of sociodemographic variables on participation, prostate cancer incidence and mortality
(
- Contribution to journal › Article
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article
- 2017
-
Mark
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
(
- Contribution to journal › Article
- 2016
-
Mark
Porous silicon microarray for simultaneous fluorometric immunoassay of the biomarkers prostate-specific antigen and human glandular kallikrein 2
(
- Contribution to journal › Article
-
Mark
Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections
(
- Contribution to journal › Article
- 2015
-
Mark
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality
(
- Contribution to journal › Article
- 2014
-
Mark
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
Emerging PSA-based tests to improve screening
(
- Contribution to journal › Scientific review
-
Mark
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival
(
- Contribution to journal › Article
- 2013
-
Mark
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
(
- Contribution to journal › Article
- 2012
-
Mark
Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men
(
- Contribution to journal › Article
-
Mark
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
(
- Contribution to journal › Article
-
Mark
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators : Results from the prostate biopsy collaborative group
(
- Contribution to journal › Article
- 2011
-
Mark
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(145) or Lys(146) from fPSA without internal cleavages at Lys(145) or Lys(146)
(
- Contribution to journal › Article
-
Mark
Prediction of Significant Prostate Cancer Diagnosed 20 to 30 Years Later With a Single Measure of Prostate-Specific Antigen at or Before Age 50
(
- Contribution to journal › Article
-
Mark
TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
(
- Contribution to journal › Article
-
Mark
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer : Preliminary analysis of the results of the IMPACT study
(
- Contribution to journal › Article
- 2010
-
Mark
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
(
- Contribution to journal › Article
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
-
Mark
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Prostate cancer early detection : Clinical practice guidelines in oncology™
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Risk of Dying From Prostate Cancer in Men Randomized to Screening Differences Between Attendees and Nonattendees
(
- Contribution to journal › Article
-
Mark
Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
(
- Contribution to journal › Article
-
Mark
Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort
(
- Contribution to journal › Article
-
Mark
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer
(
- Contribution to journal › Scientific review
- 2008
-
Mark
Serum Markers for Prostate Cancer : A Rational Approach to the Literature
(
- Contribution to journal › Scientific review
-
Mark
Screening for prostate cancer : an update.
(
- Contribution to journal › Scientific review
- 2007
-
Mark
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy
(
- Contribution to journal › Article
-
Mark
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - Results from a prospective, population-based randomized controlled trial
(
- Contribution to journal › Article
-
Mark
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section
(
- Contribution to journal › Article
- 2006
-
Mark
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
(
- Contribution to journal › Article
- 2005
-
Mark
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue
(
- Contribution to journal › Article
-
Mark
beta-Microseminoprotein binds CRISP-3 in human seminal plasma
(
- Contribution to journal › Article
- 2004
-
Mark
Lead time associated with screening for prostate cancer
(
- Contribution to journal › Article
-
Mark
An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6
(
- Contribution to journal › Article
-
Mark
Isoformen des freien prostataspezifischen Antigens
(
- Contribution to journal › Article
-
Mark
Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio
(
- Contribution to journal › Article
- 2003
-
Mark
Quantitative PSA RT-PCR for preoperative staging of prostate cancer
(
- Contribution to journal › Article
-
Mark
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
(
- Contribution to journal › Article
-
Mark
Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden
(
- Contribution to journal › Article
- 2002
-
Mark
Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
(
- Contribution to journal › Article
- 2001
-
Mark
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
(
- Contribution to journal › Article
-
Mark
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing
(
- Contribution to journal › Article
- 2000
-
Mark
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
(
- Contribution to journal › Article
- 1999
-
Mark
The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
(
- Contribution to journal › Article
-
Mark
Time-resolved fluorescence imaging (TRFI) for direct immunofluorescence of PSA and alpha-1-antichymotrypsin in prostatic tissue sections
(
- Contribution to journal › Article
- 1998
-
Mark
Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling
(
- Contribution to journal › Article
-
Mark
Cloning and characterization of the α1-antichymotrypsin produced by human prostate tissue
(
- Contribution to journal › Article
- 1997
-
Mark
Individual prostate-specific antigen (PSA) forms as prostate tumor markers
(
- Contribution to journal › Article
- 1996
-
Mark
Structural investigation of the alpha-1-antichymotrypsin : Prostate-specific antigen complex by comparative model building
(
- Contribution to journal › Article
- 1992
-
Mark
Prostate specific antigen predominantly forms a complex with alpha1‐antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum
(
- Contribution to journal › Article